The Versamune® nano-platform is based on synthetic positively-charged lipids, and is protected by several patents.
Versamune® works when administered together with a disease or cancer-specific antigen to prime and target a T-cell response specifically against cells displaying that particular antigen. Treatment with Versamune®-based immunotherapies results in stimulation of both the innate and adaptive arms of the immune system. Preclinical studies also suggest significant reduction in tumor defense mechanisms, leading to powerful anti-tumor efficacy.
The Versamune® platform is built on all three critical components of cancer immunotherapy that have been demonstrated to be clinically important.